Herpes zoster virus of shingles
About us We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Read morePress releases
- IAS 2019: ViiV Healthcare showcasing innovation in HIV science
- GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
- ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Tweets from GSK
-
GSK @GSK
#FlashbackFriday to this time 50 years ago when the #Apollo11 mission headed to the moon. #DYK that some of our heritage medicines were on board? The astronauts carried tablets for travel sickness! #Apollo50th
about 8 hours ago
-
GSK @GSK
Go #BehindTheScience with @ViiVHC to find out what they have planned for #IAS2019 - the world’s largest open scientific conference on #HIV science: gsk.to/2SpTO5b twitter.com/ViiVHC/status/…
about 11 hours ago
-
GSK @GSK
HIV is a key area of research for us, through our dedicated global leading HIV company, @ViiVHC, where scientists are investigating innovative treatments to support a broad range of people living with #HIV/#AIDS. twitter.com/ViiVHC/status/…
about 1 day ago
